Munich - Delayed Quote EUR

UCB SA (UNC.MU)

Compare
188.20
-1.40
(-0.74%)
At close: January 31 at 5:27:10 PM GMT+1
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
5,252,000.00
5,252,000.00
5,517,000.00
5,777,000.00
5,347,000.00
Cost of Revenue
1,707,000.00
1,707,000.00
1,675,000.00
1,438,000.00
1,363,000.00
Gross Profit
3,545,000.00
3,545,000.00
3,842,000.00
4,339,000.00
3,984,000.00
Operating Expense
2,912,000.00
2,912,000.00
3,141,000.00
3,017,000.00
2,944,000.00
Operating Income
633,000.00
633,000.00
701,000.00
1,322,000.00
1,040,000.00
Net Non Operating Interest Income Expense
-129,000.00
-129,000.00
-64,000.00
-41,000.00
-55,000.00
Pretax Income
441,000.00
441,000.00
511,000.00
1,226,000.00
880,000.00
Tax Provision
98,000.00
98,000.00
91,000.00
170,000.00
119,000.00
Net Income Common Stockholders
343,000.00
343,000.00
418,000.00
1,058,000.00
732,000.00
Diluted NI Available to Com Stockholders
343,000.00
343,000.00
418,000.00
1,058,000.00
732,000.00
Basic EPS
1.81
1.81
2.20
5.60
3.87
Diluted EPS
1.76
1.76
2.14
5.45
3.77
Basic Average Shares
189,690.00
189,690.00
189,619.00
188,973.00
189,035.00
Diluted Average Shares
195,190.00
195,190.00
194,834.00
194,177.00
194,245.00
Total Operating Income as Reported
604,000.00
604,000.00
585,000.00
1,284,000.00
971,000.00
Total Expenses
4,619,000.00
4,619,000.00
4,816,000.00
4,455,000.00
4,307,000.00
Net Income from Continuing & Discontinued Operation
343,000.00
343,000.00
418,000.00
1,058,000.00
732,000.00
Normalized Income
341,440.00
341,440.00
503,640.00
1,019,740.00
819,000.00
Interest Income
27,000.00
27,000.00
12,000.00
7,000.00
14,000.00
Interest Expense
144,000.00
144,000.00
71,000.00
45,000.00
68,000.00
Net Interest Income
-129,000.00
-129,000.00
-64,000.00
-41,000.00
-55,000.00
EBIT
585,000.00
585,000.00
582,000.00
1,271,000.00
948,000.00
EBITDA
1,276,000.00
1,276,000.00
1,171,000.00
1,594,000.00
1,302,000.00
Reconciled Cost of Revenue
1,707,000.00
1,707,000.00
1,675,000.00
1,438,000.00
1,363,000.00
Reconciled Depreciation
691,000.00
691,000.00
589,000.00
323,000.00
354,000.00
Net Income from Continuing Operation Net Minority Interest
343,000.00
343,000.00
420,000.00
1,055,000.00
732,000.00
Total Unusual Items Excluding Goodwill
2,000.00
2,000.00
-102,000.00
41,000.00
-100,000.00
Total Unusual Items
2,000.00
2,000.00
-102,000.00
41,000.00
-100,000.00
Normalized EBITDA
1,274,000.00
1,274,000.00
1,273,000.00
1,553,000.00
1,402,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
440.00
440.00
-18,360.00
5,740.00
-13,000.00
12/31/2020 - 5/15/2001

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

1AEA.SG argenx SE
635.00
+2.42%
 
1AE.SG argenx SE
637.80
+1.75%
 
ARGX.VI argenx SE
642.80
+1.61%
 
LVTX LAVA Therapeutics N.V.
0.9800
+3.62%
 
ARGX argenx SE
655.13
-1.58%
 
CORT Corcept Therapeutics Incorporated
66.92
-4.26%
 
PPCB Propanc Biopharma, Inc.
9.00
0.00%
 
AKRO Akero Therapeutics, Inc.
54.08
-2.31%